CC BY
0©Roussou E.
This work is licensed under a Creative Commons Attribution 4.0 International L
ORIGINAL
Spondylarthritis in African Populations Compared to Europeans Living in the United Kingdom
Euthalia Roussou
Rheumatology Department, Department of Rheumatology and Rehabilitation, Barley Lanes, United Kingdom
ABSTRACT
Background: With the aim to study Spondylarthritis in patients originating from Africa and compare the disease with the way it is manifested in Europeans, data was analysed from 62 African patients and compared with 56 Europeans living in the same geographical area (north East London, United Kingdom) and treated under the same health system (NHS). Data analysed were demographic, social and clinical characteristics. Results: Comparisons showed differences in prevalence of psoriasis (more in Caucasians), uveitis (more in Africans), smoking (more in Europeans), and significantly fewer patients of African origin declared family history of SpA. African patients have less disease activity (but not significantly better measured by BASDAI), and statistically significant better functional ability (BASFI) compared to Europeans. No difference has been noted in gender distribution, age of disease onset, disease duration, delay in diagnosis, disease associations with IBD, night pain, or overall wellbeing. Conclusions: SpA is different in Africans in that it shows to be milder in terms of disease activity and functional ability with more uveitis less psoriasis and less family history of SpAs.
Mediterr J Rheumatol 2021;32(1):39-55 https://doi.org/10.31138/mjr.32.1.39
Article Submitted: 16 Dec 2019; Revised Form: 15 Mar 2020; Article Accepted: 30 Aug 2020; Available Online: 19 Oct 2020
Keywords: Spondylarthritis, Africans, Europeans, United Kingdom, NHS, comparison
INTRODUCTION
Spondylarthritis (SpA) comprises a group of inflammatory chronic diseases that share similar clinical presentations, radiological findings, human leucocyte antigen (HLA) B27 association and positive family history.1 According
to the European Spondyloarthropathy Study Group (ESSG) criteria,2 SpA has been traditionally classified as: ankylosing spon-dylitis (AS), reactive arthritis (ReA), undifferentiated SpA (uSpA), psoriatic arthritis, and arthritis associated with
inflammatory bowel disease (IBD).3 Its prevalence varies from 0.1% to 1.4% of the general population depending on the geographical region studied.4 Despite the fact that SpA affects males more frequently and severely than females, there is an increasing notion that the proportion of female patients is higher than initially thought, with women having less severe clinical manifestations.5 SpA usually begins in individuals younger than 45 years of age affecting the spine, peripheral joints, tendons and ligament insertions (entheses). It has extra-articular manifestations from the skin, mucosa, gut, and the eyes.6 HLA-B27 is considered a risk factor for the development of SpA. Although it is associated with AS (in particular), the association is variable across ethnic groups.7 The aim of the present study is to assess SpA in Africans compared to Europeans.
Corresponding Author:
Euthalia Roussou Department of Rheumatology and Rehabilitation, Barley Lanes Goodmayes, Ilford, Essex IG3 8YB, United Kingdom Tel.: +44 208 970 8160 Fax: +44 208 970 8189 E-mail: thaliaroussou@hotmail.com
Cite this article as: Roussou E. Spondyloarthritis in African Populations Compared to Europeans Living in the United Kingdom. Mediterr J 39 Rheumatol 2021;32(1):39-55.
PATIENTS AND METHODS
Patients
Patients with any form of SpA who were evaluated by a rheumatologist in the outpatient department enrolled in a clinical registry of spondyloarthritis (SpA) called London Registry of SpA (LoRoS). Our group of hospitals has a catchment area of 700,000 inhabitants with varied ethnicities. Most of the data were derived from King George Hospital (Ilford, Essex), which predominantly serves the area of Redbridge, a region with marked ethnic variation.8 Data presented in this paper were obtained from questionnaires administered to patients attending their routine outpatient clinic for rheumatology or a combined rheumatology/dermatology clinic. The patients were referred to our services by local general practitioners (GPs), consultants from other specialties within the hospitals, and by the local Musculoskeletal Clinical Assessment and Treatment (MCAT) services for back pain. These services are run by experienced physiotherapists who mainly treat mechanical back pain. Individuals with evidence of inflammatory back pain (IBP) or back pain with evidence of peripheral joint disease are flagged and referred for hospital assessment and treatment.
The baseline assessment of all referred patients included review of their medical history and clinical examination. Medical history included any family history of psoriasis, inflammatory bowel diseases, and other conditions associated with SpA, such as uveitis. Particularly attention has been given to those with history suggestive of IBP, as recommended by Calin9 and the Assessment of SpondyloArthritis criteria proposed by Rudwaleit for axial10 or peripheral SpA.11 Laboratory tests are taken place routinely and include erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) for all patients with evidence of Inflammatory arthritis. Radiological investigations included radiographs of the hands, wrists, feet, and ankles if there was evidence of peripheral disease, in addition to radiographs of the spine (cervical, thoracic, and lumbar spine), the hips, and pelvis. If sacroiliitis could not be clearly confirmed from radiographs of the hips and pelvis, (a plain anterior pelvic X-ray and a dedicated X-ray of the sacroiliac joints) a magnetic resonance imaging (MRI), usually with contrast enhancement, of the sacroiliac joints was requested as recommended before.12 Patients with confirmed SpA completed a semi-structured questionnaire, as described below.
Questionnaire
The semi-structured questionnaire was originally developed in 2001 and was validated and used in this group of patients in 2004. The data presented here were collected between 2005 and 2016.
Patients were recruited when attending the outpatient clinics of our hospital. On attendance, patients with evi-
dence of IBP and confirmed diagnosis of SpA were given the 11-page questionnaire together with an information sheet explaining the aims of the study and a consent form. The patient's questionnaire contained seven groups of questions, namely demographic data, disease onset, first symptom at disease onset, and main symptoms experienced during the disease course. Age at diagnosis, disease duration, and delay in diagnosis were obtained from the above-mentioned sections of the questionnaire. Two questions were asked about disease onset: "When do you think the disease started?", and "When was the disease diagnosed?" By comparing the two responses, we could determine whether there was a delay in diagnosis. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)13 and the Bath Ankylosing Spondylitis Function Index [BASFI]14 were both included in the questionnaire to assess disease activity and functional ability, respectively. Disease activity was also assessed in terms of ESR and CRP. Two 10 cm visual analogue scales (VAS) were also included and asked patients to state their perception of well-being and night pain over the preceding week. In both VASs, 10 cm was defined as the worst possible response. In the demographics section, the patients were asked "What is the ethnic group to which you belong?" The patients chose from five lists: Asian (Bangladeshi, Chinese, Indian, Pakistani, or other), Black (African, Afro-Caribbean, or other), European (white British, or other), mixed (describe), and other (describe). For mixed and other, the patients were able to describe their exact ethnicity if it was not stated in the provided lists. Individuals of mixed ethnicity were excluded from this study. Also, a question was included asking whether they were known to have osteoporosis and whether they ever had a DEXA scan.
The level of education they had reached, marital status and number of children was also obtained. Finally, there was a question on family history of spondyloarthritis and the degree of the relationship as described before.17
VALIDATION OF THE QUESTIONNAIRE
During the validation process, the first 50 patients filling in data were questioned to confirm their age, gender, and race. The patients' race was determined from the questions covering ethnicity and was verified by the physician. The symptoms at disease onset, clinical aspects, clinical association, employment status and family history were also tested. The symptoms at disease onset were validated with the symptoms described in the general practitioner's referral letter.
In order to validate the clinical aspects, the patient's clinician (assessor) also completed a two-page questionnaire to record clinical data such as joints with arthritis, symmetrical or asymmetrical pattern, whether they had confirmed sacroiliitis, documented inflammatory bowel disease, uveitis, previous infection (salmonella, Shigella,
Yersinia, Chlamydia) associated psoriasis, enthesitis, or Juvenile onset disease. The clinician's data were then examined against the reported patient's data from the questionnaire. There are however questions on the questionnaire such as "which is the main symptom(s) at disease onset and main problem(s) that the disease is causing to you" which are based on perception and cannot be validated by a third party.
Statistical analysis
Data are expressed as mean ± SD (except where otherwise indicated). Statistical analysis performed using x2 tests for comparisons between categorical variables (ie, sex and symptoms) and independent sample t-test was used to assess differences between means of two sets. Two-tailed p values <0.05 were considered statistically significant. For statistical analysis we used SPSS V.19.0 (SPSS Inc). For the presentation and analysis of categorical variables, frequency distribution, percentages and contingency tables were used.
Ethical approval
The study was approved by the Redbridge and Waltham Forest Ethics Committee and by the Research and Development Board of Barking Havering and Redbridge University Hospitals NHS Trust. Each patient signed an informed consent form and confidentiality was strictly maintained.
RESULTS
From a total of 776 patients that provided data and were included in a registry of spondyloarthropathies, 62 patients originating from Africa (and living in the UK) with a diagnosis of SpA according to the ESSG criteria were studied. This suggests a prevalence of 7.9% of SpA in African individuals. Their data were compared with 56 patients who had declared themselves as Europeans. All of the patients were seen at King George Hospital in North East London (Redbridge), UK, between January 2005 and December 2016. All patients were evaluated by the same rheumatologist in the outpatient department. Table 1 shows demographic, clinical, and social characteristics of the 2 groups studied, as well as differences between the 2 groups.
DISCUSSION
Our study represents a retrospective analysis of data from patients with SpA living in a defined catchment area in north East London. In this study, although the registry had 776 patients at the time of the analysis, in order to avoid bias we excluded patients declaring themselves as "British", as British identity does not distinguish race and data. Data only from patients with clear origin were used and analysed. Such a choice provided limitations in reaching statistical analysis; therefore, these results may represent initial results requiring further testing. Through the study, differences have been identified in
Table 1. Demographic, clinical, and social characteristics of the 2 groups studied.
Item African (N=62) DIAGNOSES AS = 15 (24.1%) PsA= 11 (17.7 %) ReA= 3 (4.8 %) USpA= 20 (32.2%) UC= 2 (3.2%) ACHILLES TENDINOSIS = 1 (3.2%) European (N=56) 11 (17.5%) 22 (34.6%) 1 (1.6%) 9 (13.3%) 1 (1.6%) 0 ss Comment
M/F 22/40 20/36 0.38 NS
Age (m + sd) 44.6 +12.4 46.4 + 13.6 0.5 NS
ESR 18.6 + 18.3 21.1 + 22 0.6 NS
AGE diagnosis 39 + 13.3 39.7 + 14 0.6 NS
Disease duration 10 + 9.9 11.6 + 11.1 0.9 NS
Delay in diagnosis 6.4 + 7.08 6.5 + 7.9 0.5 NS
HLA B27+ 2 6 (9.5%) 0.9 NS
SMOKING (yes) 7 (11%) 18/53 (34%) 0.001 significant
Alcohol (yes) 28 (47.5%) 37/53 (69.8%) 0.68 NS
Eye inflammation (uveitis) 14 (28.6%) 6 (11.3) 0.2 NS
Psoriasis 6 (12.8%) 16 (34%) 0.03 significant
Irritable bowel syndrome 15 (23.6%) 19 (38%) 0.3 NS
BASDAI 6.2 + 2.1 6.6. + 1.6 0.3 NS
BASFI 4.8 + 2.7 5.9 + 2.4 0.03 significant
NIGHT pain 5.8 + 3.04 6.3 + 3.3 0.5 NS
Effect of treatment (VAS) 3.8 + 2.8 3.2 + 2.8 0.1 NS
WELL being (w) 6.4 + 2.5 6 .03 + 3.01 0.2 NS
Osteoporosis 6 (10) 10% 5 (9.4%) 0.4 NS
DEXA 7 (12.5%) 9 (16.1%) 0.6 NS
Education 0 1 2 3 4 5 3 (5.5%) 4 (7.3 %) 9 (16.4%) 13 (23.6 %) 23 (41.8 %) 3 (5.5%) 4 (8%) 6 (12%) 14 (28%) 14 (28%) 12 (24%) 0.02 CI -0.098 to -1.251
Marital status 1 2 3 4 5 33 (55.9%) 20 (33.9%) 3 (5.1%) 2 (3.4%) 1 (1.7%) 32 (61%) 10 (19.2%) 4 (7.7%) 4 (7.7%) 2 (3.8%) 0.7 CI -.0512 to 0.349
Children (number of) 0 1 2 3 4 5 6 7 8 9 13 (22.8) 3 (5.3) 15 (26.3) 12 (21.1) 7(12.3) 1 (1.8) 5 (8.8) 0 0 1 (1.8%) 8 (16 %) 4(8%) 13 (26 %) 12 (24%) 8 (16 %) 3 (6%) 2 (4%) 0.4 CI -0.443 to 1.021
FX (yes) 19/52 (36.5%) 33/53 (63.5%) 0.02 CI -0.503 to -0.042
SpAs between African and European populations living in the same multi-ethnic geographical area, exposed to the same environmental (weather, food, pollution) conditions, and treated under the same health system. Results showed that although African patients with SpA have comparable gender distribution, age at disease onset, disease duration, delay in diagnosis, and clinical characteristics such as association with irritable bowel, disease activity, night pain, effect of treatment, and overall wellbeing with Europeans, they also have differences all indicative of milder disease expression in Africans. These differences are related predominantly to genetic background (defined in our study by family histo-
ry), social habits (smoking), prevalence of psoriasis and functional ability. A clearly distinct prevalent association in the African population is that of increased prevalence of uveitis (29%) compared to the prevalence seen in Europeans (11%), which, however, has not reached statistical significance levels.
With regards to genetic background, the answer to the Family history question indicates that more Europeans have reported positive family history of SpAs compared to African patients. HLA-B27 has been known for over 40 years as a predisposing factor for SpA, specifically for AS.15 In Caucasians with AS, 80-85% of patients are HLA-B27 positive. Overall, however, a small percentage
of Caucasian individuals who are HLAB27 positive will subsequently develop the disease.16 It seems that in populations other than Caucasian, HLA-B27 is less prevalent. Since it is known that the HLAB27 allele is virtually absent in Africa, it can perhaps be suggested that the genetic predisposition is HLAB27-related, and in its absence, there is no family aggregation or family predisposition.
Another interesting finding is that there is greater incidence of Psoriasis in Europeans. Our study shows that 12.8% of SpA patients of African origin have psoriasis compared to 34% of the Europeans. This is comparable with data published in a paper from South Africa18 in which in 2003 it was reported that from just over 7000 patients assessed of whom 76% were black, 10% white, and 7.6% were Indian, eczema was the most common dermatological disorder identified in the black population (37%) followed by acne (17.5%). In South Africa psoriasis was seen in a relatively small proportion (17.5%). This was from those of Asian descents rather than native African descent.
Our patients are mostly from Nigeria, and to generalize for the whole of the African continent would perhaps indicate it as an overstatement. However, by taking together these data from South Africa, and our small sample from African patients who are predominantly of Nigerian origin (representative of another African country not neighbouring to south Africa), one can assume that perhaps Africans as a whole have less psoriasis. More data are needed in the prevalence of psoriasis and pso-riatic arthritis in the African continent. Africans have better functional ability (defined by BASFI) compared to Europeans, but also better disease activity as defined by BASDAI. Smoking has been associated with increased disease activity.19 Although BASDAI was elevated in Europeans a greater percentage of whom are smokers, compared to African this difference in disease activity did not reach significance levels. This may be related to the small number of patients examined. The difference in the functional ability however between Africans and Europeans was significant indicating that African patients run milder disease. Since we have identified increased proportion of patients with uveitis, one may suggest that SpA in African populations is different with more systemic manifestations such that the one from the eyes rather than the musculoskeletal system. The notion that the SpA spectrum of diseases are not common in Africa has been suggested for many years. There are reports from South Africa stating that Spondyloarthritis has similar characteristics in South Africa as in Europe since the late 1990s and early 2000s.20-21 The fact that there has been more reactive arthritis in Africa following the spread of HIV/AIDS has not been seen in great proportion among the Africans migrating to Europe, and there was not anyone among
our patients studied, although we have seen such patients in our department.
In summary, our data suggest that African patients with spondyloarthritis in addition to less genetic predisposition manifested by low incidence of HLAB27 have milder disease compared to Europeans with less psoriasis and more uveitis.
CONFLICT OF INTEREST
The author declares no conflicts of interest.
REFERENCES
1. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
2. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
3. Dougados M, van der Heijde D. Ankylosing spondylitis: how should the disease be assessed? Best practice & research. Clin Rheumatol 2002;16:605-18.
4. Ehrenfeld M. Geoepidemiology: the environment and spondyloar-thropathies. Autoimmun Rev 2010;9:A325-9.
5. Haroon NN, Paterson JM, Li P, Haroon N. Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS. BMJ Open 2014;4:e006634.
6. Dougados M, Hochberg MC. Why is the concept of spon-dyloarthropathies important? Best Pract Res Clin Rheuma-tol 2002;16:495-505.
7. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997;49:116-23.
8. Londoner. The world in one city. January 2004, page 4. www. london.gov.uk.
9. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-4.
10. Rudvaleit M, van der Heijde, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of spondyloar-thritis international society (ASAS) classification criteria for Axial Spodyloarthritis (part II). Validation and final selection. Ann Rheum Dis 2009;(68):777-83.
11. Rudvaleit M, van der Heijde, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society (ASAS) classification criteria for peripheral Spodyloarthritis and Spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31.
12. Roussou E, Jurik AG. Difficulties for the detection of positive signs of sacroiliitis in spondyloarthritides by magnetic resonance imaging (MRI) in everyday clinical practice. Clin Exp Rheumatol 2011;29(3)594-5.
13. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
14. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol 1994; 21:2281-5.
15. Reveille JD. The genetic basis of spondyloarthritis. Ann Rheum Dis 2011;70(Suppl 1):i44-50
16. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol 2001;13:265-72.
17. Ciurtin C, Roussou E. Cross-sectional study assessing family
members of psoriatic arthritis patients affected by the same disease: differences between Caucasian, South Asian and Afro-Caribbean populations living in the same geographic region. Int J Rheum Dis 2013 Aug;16(4):418-24.
18. Hartshorne ST. Dermatological disorders in Johannesburg, South Africa. Clin Exp Derm.2003;6:661-5.
19. Zhaos S, Challoner B, Khattak M, Moots R, Goodson NJ. Increasing smoking intensity is associated with increased disease activity in axial SpA. Rheum Int 2017;37(2)239-44.
20. Burch VC , Isaacs S , Kalla AA Ethnicity and patterns of spon-dyloarthritis in South Africa-analysis of 100 patients. J Rheumatol 01 Oct 1999;26(10):2195-200.
21. Mijiyawa M, Oniankitan O, Khan MA. Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol 2000 Jul;12(4):281-6.
22. Adizie T, Moots RJ, Hodkinson B, French N, Adebajo AO. Inflammatory arthritis in HIV positive patients: A practical guide. BMC Infect Dis 2016;16:100.
Ref.no
(for office use)
LoRoS Questionnaire (version 5)
Spondyloarthropathies in multicultural populations in London.
Do you need an interpreter to fill in this questionnaire? Yes No
1. Demographics
FULL NAME: ADDRESS
. DATE (today): . _SEX:
MARITAL STATUS:
DATE OF BIRTH:
Place of birth
If born outside UK when (year) did you arrive in the UK_
E-MAIL ADDRESS (if there is any):_
NAME OF Rheumatologist:_
Contact OF DOCTOR (e-mail address/ postal or telephone): ,
To which of the following groups do you consider that you belong?
EUROPEAN
ASIAN
Bangladeshi
Chinese
Indian
Pakistani
Other-------
BLACK African Caribbean Other_
MIXED Describe
OTHER Describe
What is the main language spoken in your household? _
SMOKING
Never smoked
Ex-smoker
Smoker
Between 1-5 cigarettes/day
5-10
10-20
More than 20
DO YOU DRINK ALCOHOL?
Never
Socially
Daily
2. Clinical I (Disease onset)
a) When did your disease begin? (Year and age)_
b) When was the diagnosis made? (Year and age) .
Buttock pain
Back pain
Neck pain
Knee pain/swelling
Shoulder pain
Foot pain/swelling
Hip pain
Eye inflammation
Headache
Don't remember
Other
2
3. In your opinion, what is the main problems that the disease is causing to you?
Tiredness (Fatigue)
Neck pain
Upper back pain
Lower back pain
Stiffness
Joint pain / swelling
Pain with pressure on various areas
Other (what)
Clinical II (associations)
4) Other than joints/back pain, do you have any other problems with any of the
Heart
Lungs
Dizziness
Headaches
Numbness
Kidneys/ water works
Other
No other problems
3
SPONDYLARTHRITIS IN AFRIC^NJS 5. Have you ever had OR now have: (Tick more than one if there are many)
Eye inflammation
Psoriasis
Dry skin in your hair or itchiness
Dry skin elsewhere in body
Irritable bowel
Stomach irritation of any sort
6. Osteoporosis:
a) Have you been told that you have "brittle" bones/osteoporosis? Yes (Tick the right one for you)
b) Have you ever had the special scan (DEXA)to confirm this? Yes
\o
No
4
Clinical III (BASDAI)
7. PLEASE PLACE a vertical mark (for example__/__) on each line below indicating
your answer to each question (ranking your symptoms) relating to the PAST WEEK.
1) How would you describe the overall level of fatigue / tiredness you have experienced?
NONE _VERY SEVERE
2) How would you describe the overall level of AS neck, back or hip pain you have had? NONE _VERY SEVERE
3) How would you describe the overall level of pain/swelling in joints other than neck, back or hips you have had?
NONE _VERY SEVERE
4) How would you describe the overall level of discomfort you have had from any areas tender to touch or pressure?
NONE _VERY SEVERE
5) How would you describe the overall level of morning stiffness you have had from the time you wake up?
NONE _VERY SEVERE
6) How long does your morning stiffness last from the time you wake up in the past week?
0 1/2 1 1 1/2 2 or more
hrs hrs
a) How would you describe the overall level of night pain you have had in the past week?
NONE _VERY SEVERE
b) How would you describe the overall level of disturbance to your sleep due to your disease?
NONE _VERY SEVERE
5
8. Function: Please place a mark on each line below to indicate your level of ability with EACH OF THE FOLLOWING ACTIVITIES during PAST WEEK: (N.B. An aid is a piece of equipment which helps you to perform an action or movement)
1) Putting on your socks or tights without help or aids (eg, sock aid) EASY______________IMPOSSIBLE
2) Bending forward from the waist to pick up a pen from the floor without an aid EASY______________IMPOSSIBLE
3) Reaching up to a high shelf without help or aids (eg, helping hand) EASY______________IMPOSSIBLE
4) Getting up out of an armless dining room chair without using your hands or any other help
EASY_______________IMPOSSIBLE
5) Getting up off the floor without help from lying on your back EASY______________IMPOSSIBLE
6) Standing unsupported for 10 minutes without discomfort EASY_______________IMPOSSIBLE
7) Climbing up 12 - 15 steps without using a handrail or walking aid. One foot on each step
EASY______________IMPOSSIBLE
8) Looking over your shoulder without turning your body EASY_______________IMPOSSIBLE
9) Doing physically demanding activities (eg, physiotherapy exercises, gardening, or sports)
EASY______________IMPOSSIBLE
10) Doing a full day's activities whether it be at home or at work EASY IMPOSSIBLE
6
9. Surgery
Have you ever had surgery in any of your joints?
If yes, what surgery (in which part of your body)
yes
10. Treatment
a) Are you currently taking any medication for your disease? If "YES" are you taking
yes
no
Pain killers
Non-steroidal anti-inflammatory drugs
Steroids
Sulphasalazine
Methotrexate
Leflunomide
Cyclosporine
Anti TNF
b) Place a vertical mark (eg,_/__) on the scale below to indicate the effectiveness
that treatment has on relieving your symptoms:
NONE VERY EFFECTIVE
11. WELLBEING
a) Place a vertical mark on the scale below to indicate the effect your disease has had on your well-being over the last week:
NONE________________WORST POSSIBLE
b) Place a vertical mark on the scale below to indicate the effect your disease has had on your well-being over the last six months:
NONE WORST POSSIBLE
7
SPONDYLOARTHRITISIN AFRICANS 12. Dietary habits (Please delete appropriately or circle the right one for you)
a) Are you a vegan? (eating plant products ONLY) Yes / No
b) Are you vegetarian? Yes / No If YES, do you eat any of the following?
Eating fish Yes/No
Eating chicken Yes/No
Eating eggs Yes/No
Dairy products Yes/No
c) Do you eat fish or fish produce (ie fish oils) at least once a week Yes/No
d) Do you think any foods aggravate your joint disease? Yes /No
If Yes, any of the foods below:
Meat produce
Dairy produce
Lentils/Pulses/beans
Fruits
Alcohol
Fish
Carbohydrates (ie rice, potato, bread)
Other
e) Do you think that any food helps your disease? Yes/No
If yes, what
8
13.Education/ Occupation/Employment
a) What level of education have you reached? (Please tick each relevant box)
No school
Primary school
Secondary school
College or technical skills
Higher education
b) Are you currently employed? (incl. self-employed) YES / NO
Manual
Active (moving)
Sedentary (sitting)
Housewife
Student / artist
d) If not employed, are you
Unemployed and intending to work
Retired
Unemployed and unable to work
Are you UNEMPLOYED / RETIRED:
Solely because of your disease?
Partly because of your disease?
For reasons other than your disease?
9
14. Spondyloarthropathy Group
1a) Have you ever seen a rheumatologist YES/NO
(a specialist in arthritis)?
1b) Have you ever been tested for HLA-B27 (a gene usually associated with ankylosing spondylitis)?
YES/NO
1c) If yes, was the result:
Positive
Negative
I don't know
2. IRITIS / UVEITIS
a) Do you get iritis (uveitis)? YES/NO
b) If YES, who made the diagnosis?
GP
Rheumatologist
Eye specialist
No doctor
c) Have you had any treatment for it? YES/NO Please specify:_
d) When did your first symptom of iritis start?
Year: Age:
e) Has the uveitis resulted in persistent deterioration of vision? YES/NO
10
3. PSORIASIS
a) Do you get psoriasis? YES/NO
b) If YES, who made the diagnosis?
GP
Rheumatologist
Skin specialist
No doctor
c) Have you ever had any treatment for it? YES/NO
Please specify (what):_
d) When did your first symptom of psoriasis start? Year: Age:
e) Have you ever had sausage-like finge rs YES/NO
f) Do you have (or ever had) funny nails? YES/NO
4. ENTEROPATHIC SPONDYLOARTHROPATHIES
1. Have you ever b een diagnosed as halving:
a) Crohn's disease YES/NO
b) Ulcerative politis YES/NO
2. If YES, who made the diagnosis?
(a) (b)
GP
Rheumatologist
Gastroenterologist
No doctor
3. When did your firrtsymptom of bowel disease start? Year: Age:
11
15. Family HISTORY
a) Are you married single divorced live with partner widowed
b) Were your parents blood related in any way prior to marriage? Yes No
c) If yes what was the relationship prior to marriage?__^-^ ^-^
d) Do you have any children? Y Hd iny
If yes
e) Please put down ages and gender (M=male or F=female) of children.
Age_Sex_Age__Sex_Age__Sex_
Age_Sex_Age_Sex_Age__Sex_
f) Do you have any brothers or sisters? Y If yes, please put down their ages and gender
N
Age . Age
. Sex_ Sex
. Age _ _ Age
Sex _Sex
Age ______ Sex _
_ Age ______Sex
g) As far as you know do any other members of your family have any form of spondyloarthropathy, like:
Ankylosing spondylitis, Psoriatic arthritis, reactive arthritis, ulcerative colitis, or Crohn's disease?
Yes No
Does anybody in your family suffer with psoriasis (flaky skin)? YES/NO
If yes, what is the relationship to you?__
Does anybody in the family suffer from longstanding lower back pain? YES/NO If yes, what is the relationship to you?__
Thank you for taking your time to fill in this questionnaire!
12
